Matthew Keller
Stock Analyst at HC Wainwright & Co.
(0.33)
# 4,329
Out of 5,118 analysts
11
Total ratings
20%
Success rate
-21.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $4.08 | +169.61% | 2 | Dec 17, 2025 | |
| SXTP 60 Degrees Pharmaceuticals | Assumes: Buy | $6 | $0.55 | +984.99% | 1 | Nov 14, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $8.99 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $2.95 | +950.85% | 2 | Sep 30, 2025 | |
| FGEN FibroGen | Reiterates: Buy | $43 | $8.78 | +389.75% | 2 | Sep 24, 2025 | |
| IFRX InflaRx | Assumes: Buy | $6 | $1.02 | +488.24% | 1 | Sep 2, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.15 | +151.92% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.06 | +1,220.75% | 1 | Aug 15, 2025 |
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $4.08
Upside: +169.61%
60 Degrees Pharmaceuticals
Nov 14, 2025
Assumes: Buy
Price Target: $6
Current: $0.55
Upside: +984.99%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $8.99
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $2.95
Upside: +950.85%
FibroGen
Sep 24, 2025
Reiterates: Buy
Price Target: $43
Current: $8.78
Upside: +389.75%
InflaRx
Sep 2, 2025
Assumes: Buy
Price Target: $6
Current: $1.02
Upside: +488.24%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.15
Upside: +151.92%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $1.06
Upside: +1,220.75%